AU733967B2 - Use of 1-benzyl-3-(substituted hetaryl)-fused pyrazole derivatives for the treatment of specific disorders of the cardiovascular system and of the central nervous system - Google Patents

Use of 1-benzyl-3-(substituted hetaryl)-fused pyrazole derivatives for the treatment of specific disorders of the cardiovascular system and of the central nervous system Download PDF

Info

Publication number
AU733967B2
AU733967B2 AU50494/98A AU5049498A AU733967B2 AU 733967 B2 AU733967 B2 AU 733967B2 AU 50494/98 A AU50494/98 A AU 50494/98A AU 5049498 A AU5049498 A AU 5049498A AU 733967 B2 AU733967 B2 AU 733967B2
Authority
AU
Australia
Prior art keywords
indazole
hydroxymethylfuran
compounds
treatment
general formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU50494/98A
Other languages
English (en)
Other versions
AU5049498A (en
Inventor
Klaus Dembowsky
Achim Feurer
Chantal Furstner
Joachim Hutter
Thomas Jaetsch
Raimund Kast
Ulrich Niewohner
Elisabeth Perzborn
Johannes-Peter Stasch
Alexander Straub
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Publication of AU5049498A publication Critical patent/AU5049498A/en
Application granted granted Critical
Publication of AU733967B2 publication Critical patent/AU733967B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU50494/98A 1996-10-14 1997-10-01 Use of 1-benzyl-3-(substituted hetaryl)-fused pyrazole derivatives for the treatment of specific disorders of the cardiovascular system and of the central nervous system Ceased AU733967B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19642255 1996-10-14
DE19642255A DE19642255A1 (de) 1996-10-14 1996-10-14 Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten
PCT/EP1997/005381 WO1998016223A1 (de) 1996-10-14 1997-10-01 Verwendung von 1-benzyl-3-(substituiertes-hetaryl)-kondensierten pyrazol-derivaten zur belandlung von speziellen erkrankungen des herz-kreislaufsystems und des zentralnervensystems

Publications (2)

Publication Number Publication Date
AU5049498A AU5049498A (en) 1998-05-11
AU733967B2 true AU733967B2 (en) 2001-05-31

Family

ID=7808650

Family Applications (1)

Application Number Title Priority Date Filing Date
AU50494/98A Ceased AU733967B2 (en) 1996-10-14 1997-10-01 Use of 1-benzyl-3-(substituted hetaryl)-fused pyrazole derivatives for the treatment of specific disorders of the cardiovascular system and of the central nervous system

Country Status (21)

Country Link
US (1) US6180656B1 (enExample)
EP (1) EP0932403B1 (enExample)
JP (2) JP2001502318A (enExample)
AT (1) ATE311184T1 (enExample)
AU (1) AU733967B2 (enExample)
BR (1) BR9712304A (enExample)
CA (1) CA2268314C (enExample)
CZ (1) CZ129299A3 (enExample)
DE (2) DE19642255A1 (enExample)
EE (1) EE9900156A (enExample)
ES (1) ES2252777T3 (enExample)
HU (1) HUP9903885A3 (enExample)
ID (1) ID22162A (enExample)
IL (1) IL129318A (enExample)
NO (1) NO991685D0 (enExample)
NZ (1) NZ335091A (enExample)
PL (1) PL332719A1 (enExample)
SK (1) SK46599A3 (enExample)
TR (1) TR199900782T2 (enExample)
TW (1) TW442482B (enExample)
WO (1) WO1998016223A1 (enExample)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19744026A1 (de) * 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
DE19846514A1 (de) * 1998-10-09 2000-04-20 Bayer Ag Neue Heterocyclyl-methyl-substituierte Pyrazole
DE19853278A1 (de) 1998-11-19 2000-05-25 Aventis Pharma Gmbh Substituierte 4-Amino-2-aryl-cyclopenta[d]pyrimidine, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19904710A1 (de) 1999-02-05 2000-08-10 Aventis Pharma Gmbh Substituierte 4-Amino-2-aryl-tetrahydrochinazoline, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943636A1 (de) * 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943635A1 (de) * 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
GB0002666D0 (en) 2000-02-04 2000-03-29 Univ London Blockade of voltage dependent sodium channels
DE10021069A1 (de) * 2000-04-28 2001-10-31 Bayer Ag Substituiertes Pyrazolderivat
US6387942B2 (en) * 2000-06-19 2002-05-14 Yung Shin Pharmaceutical Ind. Co. Ltd Method of treating disorders related to protease-activated receptors-induced cell activation
KR20020001013A (ko) * 2000-06-23 2002-01-09 리팡유 트롬빈-유도 혈소판 응집 저해방법
KR20050117594A (ko) * 2000-06-23 2005-12-15 주식회사 하이닉스반도체 반도체 소자의 제조 방법
DE10054278A1 (de) * 2000-11-02 2002-05-08 Bayer Ag Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Osteoporose
DE10057751A1 (de) 2000-11-22 2002-05-23 Bayer Ag Neue Carbamat-substituierte Pyrazolopyridinderivate
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
AU2002221827A1 (en) 2000-11-22 2002-06-03 Bayer Aktiengesellschaft Novel lactame-substituted pyrazolopyridine derivatives
DE10057754A1 (de) 2000-11-22 2002-05-23 Bayer Ag Neue Sulfonamid-substituierte Pyrazolopyridinderivate
DE60201921T2 (de) 2001-01-24 2005-10-06 Yung Shin Pharmaceutical Ind. Co., Ltd. Kondensierte Pyrazolverbindungen
DE10109859A1 (de) * 2001-03-01 2002-09-05 Bayer Ag Neuartige Aminodicarbonsäurederivate
DE10109858A1 (de) 2001-03-01 2002-09-05 Bayer Ag Neuartige halogensubstituierte Aminodicarbonsäurederivate
DE10109861A1 (de) 2001-03-01 2002-09-05 Bayer Ag Neuartige seitenkettenhalogenierte Aminodicarbonsäurederivate
DE10122894A1 (de) * 2001-05-11 2002-11-14 Bayer Ag Neue Sulfonat-substituierte Pyrazolopyridinderivate
US20040077702A1 (en) * 2001-09-14 2004-04-22 Wen-Mei Fu Treatment of nuerodegenerative diseases
US7049334B2 (en) * 2001-09-14 2006-05-23 Carlsbad Technology, Inc. Enhancement of learning and memory and treatment of amnesia
TWI264304B (en) 2002-01-25 2006-10-21 Yung Shin Pharm Ind Co Ltd Methods of treating sepsis
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
JP4499721B2 (ja) * 2003-06-30 2010-07-07 ヒフ バイオ，インク． 化合物、組成物および方法
JP2005089457A (ja) * 2003-09-03 2005-04-07 Yung Shin Pharmaceutical Industry Co Ltd 骨成長を促進するまたは骨吸収を阻害するための薬剤組成物
WO2005077005A2 (en) * 2004-02-04 2005-08-25 The General Hospital Corporation Enhancing the effectiveness of an inhaled therapeutic gas
DE102005050376A1 (de) 2005-10-21 2007-05-31 Bayer Healthcare Ag Dicarbonsäure-Derivate und ihre Verwendung
DE102005050375A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Tetrazol-Derivate und ihre Verwendung
DE102005050377A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Heterocyclische Verbindungen und ihre Verwendung
DE102005050497A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Difluorphenol-Derivate und ihre Verwendung
DE102005050498A1 (de) 2005-10-21 2007-06-06 Bayer Healthcare Aktiengesellschaft Cyclopropylessigsäure-Derivate und ihre Verwendung
DE102006020327A1 (de) * 2006-04-27 2007-12-27 Bayer Healthcare Ag Heterocyclisch substituierte, anellierte Pyrazol-Derivate und ihre Verwendung
DE102006021733A1 (de) * 2006-05-09 2007-11-22 Bayer Healthcare Ag 3-Tetrazolylindazole und 3-Tetrazolylpyrazolopyridine sowie ihre Verwendung
DE102006043443A1 (de) * 2006-09-15 2008-03-27 Bayer Healthcare Ag Neue aza-bicyclische Verbindungen und ihre Verwendung
DE102006054757A1 (de) * 2006-11-21 2008-05-29 Bayer Healthcare Ag Neue aza-bicyclische Verbindungen und ihre Verwendung
DE102007015035A1 (de) 2007-03-29 2008-10-02 Bayer Healthcare Ag Substituierte Dibenzoesäure-Derivate und ihre Verwendung
DE102007015034A1 (de) * 2007-03-29 2008-10-02 Bayer Healthcare Ag Lactam-substituierte Dicarbonsäuren und ihre Verwendung
WO2008124505A2 (en) * 2007-04-05 2008-10-16 Ironwood Pharmaceuticals,Inc. Soluble guanylate cyclase (sgc) modulators for treatment of lipid related disorders
US20080252028A1 (en) * 2007-04-16 2008-10-16 Ming-Tai Huang Shock absorbing device for toy stroller
DE102007026392A1 (de) * 2007-06-06 2008-12-11 Bayer Healthcare Ag Lösungen für die Perfusion und Konservierung von Organen und Geweben
DE102007028319A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028406A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028407A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028320A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
EP2138178A1 (en) 2008-06-28 2009-12-30 Bayer Schering Pharma Aktiengesellschaft Oxazolidninones for the treatment fo chronic obstructive pulmonary disease (COPD) and/or asthma
DE102008063992A1 (de) 2008-12-19 2010-09-02 Lerner, Zinoviy, Dipl.-Ing. Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
DE102009004245A1 (de) 2009-01-09 2010-07-15 Bayer Schering Pharma Aktiengesellschaft Neue anellierte, Heteroatom-verbrückte Pyrazol- und Imidazol-Derivate und ihre Verwendung
DK3415515T3 (da) 2009-11-27 2020-03-16 Adverio Pharma Gmbh Fremgangsmåde til fremstilling af methyl-{4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}methylcarbamat
UY33041A (es) 2009-11-27 2011-06-30 Bayer Schering Pharma Aktienegesellschaft Procedimiento para la preparaciòn de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificaciòn para el uso como principio activo farmacèutico
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
ES2549979T3 (es) * 2010-05-26 2015-11-03 Adverio Pharma Gmbh El uso de estimuladores de la sGC, activadores de la sGC, solos y en combinaciones con inhibidores de la PDE5 para el tratamiento de esclerosis sistémica (EcS)
CA2803688A1 (en) 2010-06-25 2011-12-29 Bayer Intellectual Property Gmbh Use of stimulators and activators of soluble guanylate cyclase for treating sickle-cell anemia and conserving blood substitutes
JP5940062B2 (ja) 2010-07-09 2016-06-29 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 環縮合４−アミノピリミジンおよび可溶性グアニル酸シクラーゼの刺激剤としてのその使用
EP2590979A1 (de) 2010-07-09 2013-05-15 Bayer Intellectual Property GmbH Annellierte pyrimidine und triazine und ihre verwendung zur behandlung bzw. prophylaxe von herz-kreislauf-erkrankungen
DE102010031148A1 (de) 2010-07-09 2012-01-12 Bayer Schering Pharma Ag Annellierte 4-Aminopyrimidine und ihre Verwendung
DE102011007891A1 (de) 2011-04-21 2012-10-25 Bayer Pharma Aktiengesellschaft Annellierte 4-Aminopyrimidine und ihre Verwendung
DE102011003315A1 (de) 2011-01-28 2012-08-02 Bayer Schering Pharma Aktiengesellschaft Annellierte Pyrimindine und Triazine und ihre Verwendung
DE102010031149A1 (de) 2010-07-09 2012-01-12 Bayer Schering Pharma Aktiengesellschaft Annellierte Pyrimidine und Triazine und ihre Verwendung
DE102010031667A1 (de) 2010-07-22 2012-01-26 Bayer Schering Pharma Aktiengesellschaft Substituierte Methyl-pyrimidin-5-ylcarbamate und ihre Verwendung
DE102010031666A1 (de) 2010-07-22 2012-01-26 Bayer Schering Pharma Aktiengesellschaft Carbamat-substituierte Diaminopyrimidine und ihre Verwendung
DE102010031665A1 (de) 2010-07-22 2012-01-26 Bayer Schering Pharma Aktiengesellschaft Substituierte Oxazolidinone und Oxazinanone und ihre Verwendung
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
DE102010043380A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Benzyl-substituierte Carbamate und ihre Verwendung
DE102011075399A1 (de) 2011-05-06 2012-11-08 Bayer Pharma Aktiengesellschaft Substituierte Imidazopyridine und Imidazopyridazine und ihre Verwendung
DE102012200356A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte Imidazopyridine und Imidazopyridazine und ihre Verwendung
US20140171434A1 (en) 2011-01-11 2014-06-19 Bayer Pharma Aktiengessellschaft Substituted imidazopyridines and imidazopyridazines and the use thereof
DE102011007890A1 (de) 2011-04-21 2012-10-25 Bayer Pharma Aktiengesellschaft Fluoralkyl-substituierte Pyrazolopyridine und ihre Verwendung
WO2012143510A1 (de) 2011-04-21 2012-10-26 Bayer Intellectual Property Gmbh Fluoralkyl-substituierte pyrazolopyridine und ihre verwendung
DE102012200357A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Fluoralkyl-substituierte Pyrazolopyridine und ihre Verwendung
DE102011075398A1 (de) 2011-05-06 2012-11-08 Bayer Pharma Aktiengesellschaft Substituierte Imidazopyridazine und ihre Verwendung
DE102011078715A1 (de) 2011-07-06 2013-01-10 Bayer Pharma AG Heteroaryl-substituierte Pyrazolopyridine und ihre Verwendung
DE102012200354A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Heteroaryl-substituierte Pyrazolopyridine und ihre Verwendung
CN103906752B (zh) 2011-07-06 2016-08-24 拜耳知识产权有限责任公司 杂芳基取代的吡唑并吡啶及其用作可溶性鸟苷酸环化酶刺激剂的用途
BR112014005110A2 (pt) 2011-09-02 2017-04-18 Bayer Ip Gmbh pirimidinas aneladas substituídas e utilização das mesmas
DE102012200351A1 (de) 2012-01-11 2013-07-11 Bayer Pharma Aktiengesellschaft Substituierte annellierte Pyrimidine und ihre Verwendung
DE102011082041A1 (de) 2011-09-02 2013-03-07 Bayer Pharma AG Substituierte annellierte Pyrimidine und ihre Verwendung
HUE053745T2 (hu) 2011-11-25 2021-07-28 Adverio Pharma Gmbh Helyettesített 5-fluor-1H-pirazolopiridin kristályos formában
DE102012200352A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte, annellierte Imidazole und Pyrazole und ihre Verwendung
DE102012200360A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte Triazine und ihre Verwendung
DE102012200349A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte annellierte Pyrimidine und Triazine und ihre Verwendung
JP6140738B2 (ja) 2012-03-06 2017-05-31 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換アザ二環およびその使用
US9783614B2 (en) 2012-05-10 2017-10-10 Bayer Pharma Aktiengesellschaft Antibodies capable of binding to the coagulation Factor XI and/or its activated form factor Xia and uses thereof
US9126998B2 (en) 2012-11-05 2015-09-08 Bayer Pharma AG Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
US8778964B2 (en) 2012-11-05 2014-07-15 Bayer Pharma Aktiengesellschaft Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use
US8796305B2 (en) 2012-11-05 2014-08-05 Bayer Pharma Aktiengesellschaft Carboxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use
US9624214B2 (en) * 2012-11-05 2017-04-18 Bayer Pharma Aktiengesellschaft Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
CA2901636A1 (en) 2013-02-21 2014-08-28 Adverio Pharma Gmbh Forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate
HK1220974A1 (zh) 2013-03-01 2017-05-19 Bayer Pharma Aktiengesellschaft 三氟甲基取代的稠合嘧啶类及其用途
US9776997B2 (en) * 2013-06-04 2017-10-03 Bayer Pharma Aktiengesellschaft 3-aryl-substituted imidazo[1,2-A]pyridines and their use
EP2821071A1 (en) 2013-07-04 2015-01-07 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Compounds for breast cancer treatment
AP2016008970A0 (en) 2013-07-10 2016-01-31 Bayer Pharma AG Benzyl-1h-pyrazolo[3,4-b]pyridines and use thereof
WO2015011086A1 (en) 2013-07-25 2015-01-29 Bayer Pharma Aktiengesellschaft Sgc stimulators or sgc activators and pde5 inhibitors in combination with additional treatment for the therapy of cystic fibrosis
CA2920565A1 (en) 2013-08-08 2015-02-12 Bayer Pharma Aktiengesellschaft Substituted pyrazolo[1,5-a]pyridine-3-carboxamides and use thereof
WO2015106268A1 (en) 2014-01-13 2015-07-16 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
CN106459090A (zh) 2014-02-19 2017-02-22 拜耳制药股份公司 3‑(嘧啶‑2‑基)咪唑并[1,2‑a]吡啶
WO2015140199A1 (de) 2014-03-21 2015-09-24 Bayer Pharma Aktiengesellschaft Cyano-substituierte imidazo[1,2-a]pyridincarboxamide und ihre verwendung
WO2015165930A1 (de) 2014-05-02 2015-11-05 Bayer Pharma Aktiengesellschaft Enantiomere des n-(2-amino-5-fluor-2-methylpentyl)-8-[(2,6-difluorbenzyl)oxy]-2-methylimidazo[1,2-a]pyridin-3-carboxamids sowie der di- and tri-fluor-derivate zur behandlung von kardiovaskulären erkrankungen
EP3227286B1 (de) 2014-12-02 2018-12-26 Bayer Pharma Aktiengesellschaft Substituierte pyrazolo[1,5-a]pyridine und imidazo[1,2-a]pyrazine und ihre verwendung
WO2016087343A1 (de) 2014-12-02 2016-06-09 Bayer Pharma Aktiengesellschaft Heteroaryl-substituierte imidazo[1,2-a]pyridine und ihre verwendung
JP2018505885A (ja) 2015-02-05 2018-03-01 バイエル・ファルマ・アクティエンゲゼルシャフト 置換ピラゾロ［１，５−ａ］−ピリジン−３−カルボキサミドおよびその使用
CN107567451A (zh) 2015-02-05 2018-01-09 拜耳制药股份公司 作为用于治疗心血管疾病的可溶性鸟苷酸环化酶（sgc）刺激物的n‑取代的8‑[(2,6‑二氟苄基)氧基]‑2,6‑二甲基咪唑并[1,2‑a]吡嗪‑3‑甲酰胺衍生物
TN2017000465A1 (en) 2015-05-06 2019-04-12 Bayer Pharma AG The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc)
LT3325013T (lt) 2015-07-23 2020-11-10 Bayer Pharma Aktiengesellschaft Tirpios guanilatciklazės (sgc) stimuliatoriai/aktyvatoriai derinyje su nep inhibitoriumi ir (arba) angiotenzino aii antagonistu ir jų naudojimas
KR20180094965A (ko) 2015-12-14 2018-08-24 아이언우드 파마슈티컬스, 인코포레이티드 위장 괄약근 기능장애의 치료를 위한 sGC 자극제의 용도
WO2017121693A1 (de) 2016-01-15 2017-07-20 Bayer Pharma Aktiengesellschaft Substituierte thiazol- und thiadiazolamide und ihre verwendung
WO2017121692A1 (de) 2016-01-15 2017-07-20 Bayer Pharma Aktiengesellschaft Substituierte sulfamide und ihre verwendung
WO2017121700A1 (de) 2016-01-15 2017-07-20 Bayer Pharma Aktiengesellschaft 1,3-disubstituierte 1h-pyrazolo[3,4-b]pyridin- derivate und ihre verwendung als stimulatoren der löslichen guanylatcyclase
ES2985316T3 (es) 2016-10-11 2024-11-05 Bayer Pharma AG Combinación que contiene el estimulador sGC vericuguat y el antagonista de los receptores de corticoides minerales finerenona
US11331308B2 (en) 2016-10-11 2022-05-17 Bayer Pharma Aktiengesellschaft Combination containing sGC activators and mineralocorticoid receptor antagonists
WO2018111795A2 (en) 2016-12-13 2018-06-21 Ironwood Pharmaceuticals, Inc. Use of sgc stimulators for the treatment of esophageal motility disorders
WO2018184976A1 (de) 2017-04-05 2018-10-11 Bayer Pharma Aktiengesellschaft Substituierte imidazo[1,2-a]pyridincarboxamide und ihre verwendung
KR102615821B1 (ko) 2017-04-11 2023-12-21 선샤인 레이크 파르마 컴퍼니 리미티드 불소-치환된 인다졸 화합물 및 이의 용도
MA52616A (fr) 2018-05-15 2021-03-24 Bayer Ag Benzamides à substitution 1,3-thiazol-2-yl pour le traitement de maladies associées à la sensibilisation de fibres nerveuses
US12220414B2 (en) 2018-07-11 2025-02-11 Tisento Therapeutics Inc. Use of sGC stimulators for the treatment of mitochondrial disorders
WO2020164008A1 (en) 2019-02-13 2020-08-20 Bayer Aktiengesellschaft Process for the preparation of porous microparticles

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0470039A2 (en) * 1990-07-30 1992-02-05 H. Lundbeck A/S Novel 3-arylindole and 3-arylindazole derivatives
EP0667345A1 (en) * 1994-02-14 1995-08-16 Yung Shin Pharm. Ind. Co. Ltd. 1-Benzyl-3-(substituted aryl)-condensed pyrazole derivatives as inhibitors of platelet aggregation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0470039A2 (en) * 1990-07-30 1992-02-05 H. Lundbeck A/S Novel 3-arylindole and 3-arylindazole derivatives
EP0667345A1 (en) * 1994-02-14 1995-08-16 Yung Shin Pharm. Ind. Co. Ltd. 1-Benzyl-3-(substituted aryl)-condensed pyrazole derivatives as inhibitors of platelet aggregation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BLOOD, VOL.87, NO.9, 1 MAY 1996, PAGES 3758-3767 *

Also Published As

Publication number Publication date
CZ129299A3 (cs) 1999-07-14
US6180656B1 (en) 2001-01-30
NO991685L (no) 1999-04-09
CA2268314A1 (en) 1998-04-23
WO1998016223A1 (de) 1998-04-23
ES2252777T3 (es) 2006-05-16
NZ335091A (en) 2000-09-29
SK46599A3 (en) 2000-02-14
EE9900156A (et) 1999-12-15
ATE311184T1 (de) 2005-12-15
ID22162A (id) 1999-09-09
IL129318A (en) 2001-06-14
HUP9903885A2 (hu) 2000-11-28
BR9712304A (pt) 1999-08-31
CA2268314C (en) 2006-12-12
JP2001502318A (ja) 2001-02-20
JP2009114205A (ja) 2009-05-28
TR199900782T2 (xx) 1999-07-21
NO991685D0 (no) 1999-04-09
IL129318A0 (en) 2000-02-17
HUP9903885A3 (en) 2000-12-28
PL332719A1 (en) 1999-10-11
DE19642255A1 (de) 1998-04-16
DE59712501D1 (de) 2006-01-05
TW442482B (en) 2001-06-23
EP0932403B1 (de) 2005-11-30
AU5049498A (en) 1998-05-11
EP0932403A1 (de) 1999-08-04

Similar Documents

Publication Publication Date Title
CA2268314C (en) Use of condensated (hetaryl-substituted) 1-benzal-3-pyrazol derivates for treating special diseases of the cardiovascular and the central nervous systems
KR101011864B1 (ko) 카르바메이트-치환된 피라졸로피리딘
US6833364B1 (en) Substituted pyrazole derivatives
JP6324956B2 (ja) 置換アミノインダン−およびアミノテトラリンカルボン酸ならびにその使用
JP2004520285A (ja) 新規なラクタム置換ピラゾロピリジン誘導体
RS53028B (sr) Derivati pirazolo piridina kao inhibitori nadph oksidaze
HK1223355A1 (zh) 作为ep4配体的苯并咪唑衍生物
JP2005530789A (ja) ２−（１−ベンジル−１ｈ−ピラゾロ（３，４−ｂ）ピリジン−３−イル）−５−（４−ピリジニル）−４−ピリミジンアミン誘導体およびグアニル酸シクラーゼ刺激因子としてのそれらの使用
SK112395A3 (en) Imidazopyridine derivative, preparation method thereof and pharmaceutical composition containing same
EP1339714A1 (de) Neue sulfonamid-substituierte pyrazolopyridinderivate
JP2002527435A (ja) 新規なヘテロシクリル−メチル置換ピラゾール類
KR102473680B1 (ko) 신규한 피라졸 유도체
WO2018214796A1 (zh) 一类异吲哚酮-酰亚胺环-1,3-二酮-2-烯化合物、其组合物和用途
OA10189A (en) Use of indole derivatives as 5htl agonists
JP2005504093A (ja) 内因性テストステロンレベルの増加方法
US20090005430A1 (en) Receptor Blocker and Vasodilator Comprising Indole Derivative as Active Ingredient
WO2020249117A1 (zh) 抗高血压的多元醇化合物及其衍生物
BG107139A (bg) Инхибитор тип 1 (nнe-1) обменящ натрий - водород
MXPA99003433A (en) Use of condensated (hetaryl-substituted) 1-benzal-3-pyrazol derivates for treating special diseases of the cardiovascular and the central nervous systems
TWI325317B (en) Appetite-stimulating agents and remedies for anorexia
CN1240354A (zh) 1－苄基－3－取代杂芳基稠合吡唑衍生物用于治疗心血管系统和中枢神经系统特异性疾病的应用
HK1022646A (en) Use of 1-benzyl-3-(substituted hetaryl)- fused pyrazole derivatives for treating special diseases of the cardiovascular and the central nervous systems
TW379220B (en) Pyrazolidine derivative, radical scavenger, brain--infarction depressant, and brain-edma depressant
WO1991016311A1 (fr) Derive d'acide 7-(hydrazino substitue)-4-oxoquinoline-3-carboxylique, son sel et son ester

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired